Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
For 2021, the 30 countries in the European Union/European Economic Area (EU/EEA) reported a total of 33 527 tuberculosis (TB) cases (7.4 per 100 000 population).
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.